Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.61 |
| ▸ | SRC | P12931 | 4/20 | 0.61 |
| ▸ | CSK | P41240 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 2/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 8/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | FLT4 | P35916 | 4/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198475 | 0.88 | KDR (0.62) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL2136783 | 0.84 | EGFR (0.74) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL3184407 | 0.83 | KDR (0.68) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL6444241 | 0.82 | KDR (0.59) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL2136853 | 0.81 | KDR (0.74) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL3131165 | 0.80 | EGFR (0.75) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL664787 | 0.80 | EPHA2 (0.52) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL17179600 | 0.80 | EPHA2 (0.52) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL17179598 | 0.79 | KDR (0.65) | KDRSRCCSKTEKEPHA2 | |
| SCHEMBL3193382 | 0.78 | SRC (0.60) | KDRSRCCSKTEKEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | KDR 5/4885SRC 1/4885CSK 55/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | KDR 825/4885SRC 1/4885CSK 38/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | KDR 10/4885SRC 1/4885CSK 27/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | KDR 118/4885SRC 1/4885CSK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.